|
ANXA1 |
annexin A1 |
- G alpha (q) signalling events
- G alpha (i) signalling events
- Formyl peptide receptors bind formyl peptides and many other ligands
- Smooth Muscle Contraction
- Interleukin-4 and Interleukin-13 signaling
- Developmental Lineage of Pancreatic Ductal Cells
|
- Amcinonide
- Fluocinolone acetonide
- Hydrocortisone
- Methylprednisolone
- Clobetasol propionate
- Budesonide
- Dexamethasone
- Cortisone acetate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
|
|
|
ARHGAP1 |
Rho GTPase activating protein 1 |
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- RND2 GTPase cycle
|
|
|
|
BTG3 |
BTG anti-proliferation factor 3 |
|
|
|
|
CCR7 |
C-C motif chemokine receptor 7 |
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
|
|
|
CCT2 |
chaperonin containing TCP1 subunit 2 |
- Prefoldin mediated transfer of substrate to CCT/TriC
- Formation of tubulin folding intermediates by CCT/TriC
- Folding of actin by CCT/TriC
- Association of TriC/CCT with target proteins during biosynthesis
- Association of TriC/CCT with target proteins during biosynthesis
- BBSome-mediated cargo-targeting to cilium
- Neutrophil degranulation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- RHOBTB2 GTPase cycle
- RHOBTB1 GTPase cycle
|
|
|
|
CDC37L1 |
cell division cycle 37 like 1, HSP90 cochaperone |
|
|
|
|
CDK4 |
cyclin dependent kinase 4 |
- SCF(Skp2)-mediated degradation of p27/p21
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- RMTs methylate histone arginines
- Transcriptional regulation of white adipocyte differentiation
- Cyclin D associated events in G1
- Ubiquitin-dependent degradation of Cyclin D
- Ubiquitin-dependent degradation of Cyclin D
- PTK6 Regulates Cell Cycle
- Transcriptional regulation by RUNX2
- Meiotic recombination
- Transcriptional regulation of granulopoiesis
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
- Drug-mediated inhibition of CDK4/CDK6 activity
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
|
- Purvalanol
- Alvocidib
- Palbociclib
- Ribociclib
- Abemaciclib
- Fostamatinib
- Trilaciclib
|
- Malignant melanoma
- Glioma
- Cervical cancer
|
|
CDKN2A |
cyclin dependent kinase inhibitor 2A |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
- Transcriptional Regulation by VENTX
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
- Apoptotic factor-mediated response
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of transcription factors
- Regulation of TP53 Degradation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
- Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
- Evasion of Oncogene Induced Senescence Due to p14ARF Defects
- Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
- Nuclear events mediated by NFE2L2
|
|
- Chronic myeloid leukemia (CML)
- Non-small cell lung cancer
- Malignant islet cell carcinoma
- Adult T-cell leukemia
- Esophageal cancer
- Glioma
- Pancreatic cancer
- Nasopharyngeal cancer
- Hepatocellular carcinoma
- Squamous cell carcinoma
- Penile cancer
- Oral cancer
- Malignant melanoma
- Burkitt lymphoma
- Gallbladder cancer
- Bladder cancer
- Laryngeal cancer
- Cholangiocarcinoma
- Malignant pleural mesothelioma
- Osteosarcoma
- Type II diabetes mellitus
|
|
CETN3 |
centrin 3 |
|
|
|
|
CHORDC1 |
cysteine and histidine rich domain containing 1 |
|
|
|
|
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- AKT phosphorylates targets in the cytosol
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Constitutive Signaling by AKT1 E17K in Cancer
- NIK-->noncanonical NF-kB signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- Regulation of NF-kappa B signaling
- PKR-mediated signaling
- SLC15A4:TASL-dependent IRF5 activation
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Modulation of host responses by IFN-stimulated genes
|
- Aminosalicylic acid
- Mesalazine
- Acetylcysteine
|
|
|
CLIC4 |
chloride intracellular channel 4 |
|
|
|
|
CSNK2A1 |
casein kinase 2 alpha 1 |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
- KEAP1-NFE2L2 pathway
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- Maturation of hRSV A proteins
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
- Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
- ATP
- (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Quercetin
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- Emodin
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- Dichlororibofuranosylbenzimidazole
- Quinalizarin
- Ellagic acid
- Fostamatinib
|
|
|
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
- Androgen biosynthesis
- Glucocorticoid biosynthesis
- Defective CYP17A1 causes AH5
|
- NADH
- Progesterone
- Spironolactone
- Ketoconazole
- Levoketoconazole
- Abiraterone
- Cannabidiol
- Medical Cannabis
- Nabiximols
|
- Congenital adrenal hyperplasia (CAH)
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
|
|
DDX24 |
DEAD-box helicase 24 |
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Respiratory syncytial virus (RSV) attachment and entry
- Developmental Lineage of Mammary Gland Myoepithelial Cells
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Poziotinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
- Mobocertinib
- Almonertinib
- Amivantamab
|
- Laryngeal cancer
- Cervical cancer
- Oral cancer
- Gastric cancer
- Choriocarcinoma
- Esophageal cancer
- Glioma
- Bladder cancer
|
|
ENO1 |
enolase 1 |
- Glycolysis
- Gluconeogenesis
- Manipulation of host energy metabolism
|
- Zinc
- Copper
- Artenimol
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Myoepithelial Cells
- Developmental Lineage of Mammary Stem Cells
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Pancreatic cancer
- Gastric cancer
- Ovarian cancer
- Choriocarcinoma
- Endometrial Cancer
- Bladder cancer
|
|
ESR1 |
estrogen receptor 1 |
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- RUNX1 regulates estrogen receptor mediated transcription
- ESR-mediated signaling
- RUNX1 regulates transcription of genes involved in WNT signaling
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
- Mitochondrial unfolded protein response (UPRmt)
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated estrogens
- Desogestrel
- Levonorgestrel
- Progesterone
- Lindane
- Raloxifene
- Toremifene
- Medroxyprogesterone acetate
- Testosterone
- Mitotane
- Estrone
- Tamoxifen
- Hexachlorophene
- Estradiol
- Ethynodiol diacetate
- Dobutamine
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinylestradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Oxybenzone
- Allylestrenol
- Zinc
- Genistein
- Prasterone
- Benzophenone
- Equilin
- Compound 19
- Resveratrol
- Compound 18
- Phthalic Acid
- Pyrazole
- Stanolone
- Naringenin
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Quercetin
- Afimoxifene
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estrone sulfate
- Quinestrol
- Phenolphthalein
- Permethrin
- Ospemifene
- AP1081
- Custirsen
- NP-50301
- CHF 4227
- TAS-108
- Lasofoxifene
- Arzoxifene
- Elacestrant
- Bazedoxifene
- Methyltestosterone
- beta-Naphthoflavone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- din-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- Hexestrol
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- Erteberel
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Tibolone
- Eugenol
- Synthetic Conjugated Estrogens, A
- Synthetic Conjugated Estrogens, B
- Polyestradiol phosphate
- Norethynodrel
- Octocrylene
- Homosalate
- Enzacamene
- Zeranol
- Ractopamine
- Gestrinone
- Estetrol
- Propyl Gallate
- Ormeloxifene
- 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
- Testosterone cypionate
- Testosterone enanthate
- Stanolone acetate
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
- Estriol tripropionate
- Fluoroestradiol F-18
|
|
|
ESRRB |
estrogen related receptor beta |
- Nuclear Receptor transcription pathway
|
- Diethylstilbestrol
- Genistein
- Flavone
|
|